Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.24.1.1.u2
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 2,071,989 $ 3,483,501
Prepaid expenses and other current assets 371,212 382,273
Total current assets 2,443,201 3,865,774
Prepaid research and development expense 1,090,750 1,090,750
Operating lease right-of-use assets 9,811
Total assets 3,533,951 4,966,335
Current liabilities:    
Accounts payable and accrued expenses 781,846 1,475,667
Short-term notes payable 126,840 312,703
Operating lease liabilities - Current 9,811
Total liabilities 908,686 1,798,181
Shareholders’ equity:    
Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000 and 5,417,000 Series A shares, 4,050,000 and 4,050,000 Series B shares, -0- and -0- Series C shares, 7,488,692 and 7,488,692 Series F shares outstanding at March 31, 2024 and December 31, 2023, respectively 1,592,723 1,592,723
Common stock, $0.001 par value; 350,000,000 shares authorized and 4,480,693 and 3,080,693 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 4,480 3,081
Additional paid-in capital 209,697,149 207,790,604
Accumulated Deficit (208,669,087) (206,218,254)
Total shareholders’ equity 2,625,265 3,168,154
Total liabilities and shareholders’ equity $ 3,533,951 $ 4,966,335